Signalling lymphocytic activation molecule-F7 (SLAMF7). Studies have shown that SLAMF7 is overexpressed on multiple myeloma cell surfaces in studies and is therefore considered a target of multiple myeloma therapy [57]. This evidence concerns the gene SLAMF7 and AL amyloidosis.